Global Neurodegenerative Disease CDMO Market Research Report 2026(Status and Outlook)
Neurodegenerative disease CDMO is a contract research and development and manufacturing organization that focuses on the field of neurodegenerative diseases and provides pharmaceutical companies and scientific research institutions with a full range of services from drug discovery, preclinical research to commercial production. Its core is to develop innovative therapies for the complex pathologies of diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease (such as abnormal protein aggregation, neuroinflammation, mitochondrial dysfunction, etc.) by integrating professional technology platforms such as neuroscience, protein engineering, cell therapy, and gene therapy. It also relies on a deep understanding of the special requirements of regulatory agencies such as the FDA and EMA (such as biomarker verification and long-term safety assessment) to ensure that research and development and production meet international standards, ultimately accelerating the launch of drugs for the treatment of neurodegenerative diseases.
The global Neurodegenerative Disease CDMO market size was estimated at USD 735.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.90% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neurodegenerative Disease CDMO market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neurodegenerative Disease CDMO market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neurodegenerative Disease CDMO market.
Global Neurodegenerative Disease CDMO Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
AC Immune
Alterity Therapeutics
Biogen
Charles River Laboratories
Coave Therapeutics
Sysmex Corp
Donanemab
Eisai
Fujirebio Holdings
GenSight Biologics
Neuropore Therapies
Nevrargenics
PPD
Samsung Biologics
Sanofi(Vigil Neuroscience)
Market Segmentation (by Type)
Small Molecule Drug CDMO
Biopharmaceutical CDMO
Cell and Gene Therapy (CGT) CDMO
OtherS
Market Segmentation (by Application)
Alzheimer's Disease
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)
Multiple System Atrophy (MSA)
Progressive Supranuclear Palsy (PSP)
Others
Geographic Segmentation
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Neurodegenerative Disease CDMO Market
Overview of the regional outlook of the Neurodegenerative Disease CDMO Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurodegenerative Disease CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurodegenerative Disease CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Neurodegenerative Disease CDMO market size was estimated at USD 735.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.90% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neurodegenerative Disease CDMO market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neurodegenerative Disease CDMO market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neurodegenerative Disease CDMO market.
Global Neurodegenerative Disease CDMO Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
AC Immune
Alterity Therapeutics
Biogen
Charles River Laboratories
Coave Therapeutics
Sysmex Corp
Donanemab
Eisai
Fujirebio Holdings
GenSight Biologics
Neuropore Therapies
Nevrargenics
PPD
Samsung Biologics
Sanofi(Vigil Neuroscience)
Market Segmentation (by Type)
Small Molecule Drug CDMO
Biopharmaceutical CDMO
Cell and Gene Therapy (CGT) CDMO
OtherS
Market Segmentation (by Application)
Alzheimer's Disease
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)
Multiple System Atrophy (MSA)
Progressive Supranuclear Palsy (PSP)
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Neurodegenerative Disease CDMO Market
Overview of the regional outlook of the Neurodegenerative Disease CDMO Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurodegenerative Disease CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurodegenerative Disease CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Neurodegenerative Disease CDMO
1.2 Key Market Segments
1.2.1 Neurodegenerative Disease CDMO Segment by Type
1.2.2 Neurodegenerative Disease CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURODEGENERATIVE DISEASE CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURODEGENERATIVE DISEASE CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neurodegenerative Disease CDMO Product Life Cycle
3.3 Global Neurodegenerative Disease CDMO Revenue Market Share by Company (2020-2025)
3.4 Neurodegenerative Disease CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Headquarters, Areas Served, and Product Types of Major Players
3.6 Neurodegenerative Disease CDMO Market Competitive Situation and Trends
3.6.1 Neurodegenerative Disease CDMO Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neurodegenerative Disease CDMO Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DISEASE CDMO VALUE CHAIN ANALYSIS
4.1 Neurodegenerative Disease CDMO Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURODEGENERATIVE DISEASE CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neurodegenerative Disease CDMO Market Porter's Five Forces Analysis
6 NEURODEGENERATIVE DISEASE CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurodegenerative Disease CDMO Market by Type (2020-2025)
6.3 Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (2021-2025)
7 NEURODEGENERATIVE DISEASE CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurodegenerative Disease CDMO Market Size (M USD) by Application (2020-2025)
7.3 Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application (2021-2025)
8 NEURODEGENERATIVE DISEASE CDMO MARKET SEGMENTATION BY REGION
8.1 Global Neurodegenerative Disease CDMO Market Size by Region
8.1.1 Global Neurodegenerative Disease CDMO Market Size by Region
8.1.2 Global Neurodegenerative Disease CDMO Market Size Market Share by Region
8.2 North America
8.2.1 North America Neurodegenerative Disease CDMO Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neurodegenerative Disease CDMO Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Spain
8.4 Asia Pacific
8.4.1 Asia Pacific Neurodegenerative Disease CDMO Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neurodegenerative Disease CDMO Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neurodegenerative Disease CDMO Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 AC Immune
9.1.1 AC Immune Basic Information
9.1.2 AC Immune Neurodegenerative Disease CDMO Product Overview
9.1.3 AC Immune Neurodegenerative Disease CDMO Product Market Performance
9.1.4 AC Immune SWOT Analysis
9.1.5 AC Immune Business Overview
9.1.6 AC Immune Recent Developments
9.2 Alterity Therapeutics
9.2.1 Alterity Therapeutics Basic Information
9.2.2 Alterity Therapeutics Neurodegenerative Disease CDMO Product Overview
9.2.3 Alterity Therapeutics Neurodegenerative Disease CDMO Product Market Performance
9.2.4 Alterity Therapeutics SWOT Analysis
9.2.5 Alterity Therapeutics Business Overview
9.2.6 Alterity Therapeutics Recent Developments
9.3 Biogen
9.3.1 Biogen Basic Information
9.3.2 Biogen Neurodegenerative Disease CDMO Product Overview
9.3.3 Biogen Neurodegenerative Disease CDMO Product Market Performance
9.3.4 Biogen SWOT Analysis
9.3.5 Biogen Business Overview
9.3.6 Biogen Recent Developments
9.4 Charles River Laboratories
9.4.1 Charles River Laboratories Basic Information
9.4.2 Charles River Laboratories Neurodegenerative Disease CDMO Product Overview
9.4.3 Charles River Laboratories Neurodegenerative Disease CDMO Product Market Performance
9.4.4 Charles River Laboratories Business Overview
9.4.5 Charles River Laboratories Recent Developments
9.5 Coave Therapeutics
9.5.1 Coave Therapeutics Basic Information
9.5.2 Coave Therapeutics Neurodegenerative Disease CDMO Product Overview
9.5.3 Coave Therapeutics Neurodegenerative Disease CDMO Product Market Performance
9.5.4 Coave Therapeutics Business Overview
9.5.5 Coave Therapeutics Recent Developments
9.6 Sysmex Corp
9.6.1 Sysmex Corp Basic Information
9.6.2 Sysmex Corp Neurodegenerative Disease CDMO Product Overview
9.6.3 Sysmex Corp Neurodegenerative Disease CDMO Product Market Performance
9.6.4 Sysmex Corp Business Overview
9.6.5 Sysmex Corp Recent Developments
9.7 Donanemab
9.7.1 Donanemab Basic Information
9.7.2 Donanemab Neurodegenerative Disease CDMO Product Overview
9.7.3 Donanemab Neurodegenerative Disease CDMO Product Market Performance
9.7.4 Donanemab Business Overview
9.7.5 Donanemab Recent Developments
9.8 Eisai
9.8.1 Eisai Basic Information
9.8.2 Eisai Neurodegenerative Disease CDMO Product Overview
9.8.3 Eisai Neurodegenerative Disease CDMO Product Market Performance
9.8.4 Eisai Business Overview
9.8.5 Eisai Recent Developments
9.9 Fujirebio Holdings
9.9.1 Fujirebio Holdings Basic Information
9.9.2 Fujirebio Holdings Neurodegenerative Disease CDMO Product Overview
9.9.3 Fujirebio Holdings Neurodegenerative Disease CDMO Product Market Performance
9.9.4 Fujirebio Holdings Business Overview
9.9.5 Fujirebio Holdings Recent Developments
9.10 GenSight Biologics
9.10.1 GenSight Biologics Basic Information
9.10.2 GenSight Biologics Neurodegenerative Disease CDMO Product Overview
9.10.3 GenSight Biologics Neurodegenerative Disease CDMO Product Market Performance
9.10.4 GenSight Biologics Business Overview
9.10.5 GenSight Biologics Recent Developments
9.11 Neuropore Therapies
9.11.1 Neuropore Therapies Basic Information
9.11.2 Neuropore Therapies Neurodegenerative Disease CDMO Product Overview
9.11.3 Neuropore Therapies Neurodegenerative Disease CDMO Product Market Performance
9.11.4 Neuropore Therapies Business Overview
9.11.5 Neuropore Therapies Recent Developments
9.12 Nevrargenics
9.12.1 Nevrargenics Basic Information
9.12.2 Nevrargenics Neurodegenerative Disease CDMO Product Overview
9.12.3 Nevrargenics Neurodegenerative Disease CDMO Product Market Performance
9.12.4 Nevrargenics Business Overview
9.12.5 Nevrargenics Recent Developments
9.13 PPD
9.13.1 PPD Basic Information
9.13.2 PPD Neurodegenerative Disease CDMO Product Overview
9.13.3 PPD Neurodegenerative Disease CDMO Product Market Performance
9.13.4 PPD Business Overview
9.13.5 PPD Recent Developments
9.14 Samsung Biologics
9.14.1 Samsung Biologics Basic Information
9.14.2 Samsung Biologics Neurodegenerative Disease CDMO Product Overview
9.14.3 Samsung Biologics Neurodegenerative Disease CDMO Product Market Performance
9.14.4 Samsung Biologics Business Overview
9.14.5 Samsung Biologics Recent Developments
9.15 Sanofi(Vigil Neuroscience)
9.15.1 Sanofi(Vigil Neuroscience) Basic Information
9.15.2 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Overview
9.15.3 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Market Performance
9.15.4 Sanofi(Vigil Neuroscience) Business Overview
9.15.5 Sanofi(Vigil Neuroscience) Recent Developments
10 NEURODEGENERATIVE DISEASE CDMO MARKET FORECAST BY REGION
10.1 Global Neurodegenerative Disease CDMO Market Size Forecast
10.2 Global Neurodegenerative Disease CDMO Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Neurodegenerative Disease CDMO Market Size Forecast by Country
10.2.3 Asia Pacific Neurodegenerative Disease CDMO Market Size Forecast by Region
10.2.4 South America Neurodegenerative Disease CDMO Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Sales of Neurodegenerative Disease CDMO by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
11.1 Global Neurodegenerative Disease CDMO Market Forecast by Type (2026-2035)
11.1.1 Global Neurodegenerative Disease CDMO Market Size Forecast by Type (2026-2035)
11.2 Global Neurodegenerative Disease CDMO Market Forecast by Application (2026-2035)
11.2.1 Global Neurodegenerative Disease CDMO Market Size (M USD) Forecast by Application (2026-2035)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Neurodegenerative Disease CDMO
1.2 Key Market Segments
1.2.1 Neurodegenerative Disease CDMO Segment by Type
1.2.2 Neurodegenerative Disease CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURODEGENERATIVE DISEASE CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURODEGENERATIVE DISEASE CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neurodegenerative Disease CDMO Product Life Cycle
3.3 Global Neurodegenerative Disease CDMO Revenue Market Share by Company (2020-2025)
3.4 Neurodegenerative Disease CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Headquarters, Areas Served, and Product Types of Major Players
3.6 Neurodegenerative Disease CDMO Market Competitive Situation and Trends
3.6.1 Neurodegenerative Disease CDMO Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neurodegenerative Disease CDMO Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DISEASE CDMO VALUE CHAIN ANALYSIS
4.1 Neurodegenerative Disease CDMO Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURODEGENERATIVE DISEASE CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neurodegenerative Disease CDMO Market Porter's Five Forces Analysis
6 NEURODEGENERATIVE DISEASE CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurodegenerative Disease CDMO Market by Type (2020-2025)
6.3 Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (2021-2025)
7 NEURODEGENERATIVE DISEASE CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurodegenerative Disease CDMO Market Size (M USD) by Application (2020-2025)
7.3 Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application (2021-2025)
8 NEURODEGENERATIVE DISEASE CDMO MARKET SEGMENTATION BY REGION
8.1 Global Neurodegenerative Disease CDMO Market Size by Region
8.1.1 Global Neurodegenerative Disease CDMO Market Size by Region
8.1.2 Global Neurodegenerative Disease CDMO Market Size Market Share by Region
8.2 North America
8.2.1 North America Neurodegenerative Disease CDMO Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neurodegenerative Disease CDMO Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Spain
8.4 Asia Pacific
8.4.1 Asia Pacific Neurodegenerative Disease CDMO Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neurodegenerative Disease CDMO Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neurodegenerative Disease CDMO Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 AC Immune
9.1.1 AC Immune Basic Information
9.1.2 AC Immune Neurodegenerative Disease CDMO Product Overview
9.1.3 AC Immune Neurodegenerative Disease CDMO Product Market Performance
9.1.4 AC Immune SWOT Analysis
9.1.5 AC Immune Business Overview
9.1.6 AC Immune Recent Developments
9.2 Alterity Therapeutics
9.2.1 Alterity Therapeutics Basic Information
9.2.2 Alterity Therapeutics Neurodegenerative Disease CDMO Product Overview
9.2.3 Alterity Therapeutics Neurodegenerative Disease CDMO Product Market Performance
9.2.4 Alterity Therapeutics SWOT Analysis
9.2.5 Alterity Therapeutics Business Overview
9.2.6 Alterity Therapeutics Recent Developments
9.3 Biogen
9.3.1 Biogen Basic Information
9.3.2 Biogen Neurodegenerative Disease CDMO Product Overview
9.3.3 Biogen Neurodegenerative Disease CDMO Product Market Performance
9.3.4 Biogen SWOT Analysis
9.3.5 Biogen Business Overview
9.3.6 Biogen Recent Developments
9.4 Charles River Laboratories
9.4.1 Charles River Laboratories Basic Information
9.4.2 Charles River Laboratories Neurodegenerative Disease CDMO Product Overview
9.4.3 Charles River Laboratories Neurodegenerative Disease CDMO Product Market Performance
9.4.4 Charles River Laboratories Business Overview
9.4.5 Charles River Laboratories Recent Developments
9.5 Coave Therapeutics
9.5.1 Coave Therapeutics Basic Information
9.5.2 Coave Therapeutics Neurodegenerative Disease CDMO Product Overview
9.5.3 Coave Therapeutics Neurodegenerative Disease CDMO Product Market Performance
9.5.4 Coave Therapeutics Business Overview
9.5.5 Coave Therapeutics Recent Developments
9.6 Sysmex Corp
9.6.1 Sysmex Corp Basic Information
9.6.2 Sysmex Corp Neurodegenerative Disease CDMO Product Overview
9.6.3 Sysmex Corp Neurodegenerative Disease CDMO Product Market Performance
9.6.4 Sysmex Corp Business Overview
9.6.5 Sysmex Corp Recent Developments
9.7 Donanemab
9.7.1 Donanemab Basic Information
9.7.2 Donanemab Neurodegenerative Disease CDMO Product Overview
9.7.3 Donanemab Neurodegenerative Disease CDMO Product Market Performance
9.7.4 Donanemab Business Overview
9.7.5 Donanemab Recent Developments
9.8 Eisai
9.8.1 Eisai Basic Information
9.8.2 Eisai Neurodegenerative Disease CDMO Product Overview
9.8.3 Eisai Neurodegenerative Disease CDMO Product Market Performance
9.8.4 Eisai Business Overview
9.8.5 Eisai Recent Developments
9.9 Fujirebio Holdings
9.9.1 Fujirebio Holdings Basic Information
9.9.2 Fujirebio Holdings Neurodegenerative Disease CDMO Product Overview
9.9.3 Fujirebio Holdings Neurodegenerative Disease CDMO Product Market Performance
9.9.4 Fujirebio Holdings Business Overview
9.9.5 Fujirebio Holdings Recent Developments
9.10 GenSight Biologics
9.10.1 GenSight Biologics Basic Information
9.10.2 GenSight Biologics Neurodegenerative Disease CDMO Product Overview
9.10.3 GenSight Biologics Neurodegenerative Disease CDMO Product Market Performance
9.10.4 GenSight Biologics Business Overview
9.10.5 GenSight Biologics Recent Developments
9.11 Neuropore Therapies
9.11.1 Neuropore Therapies Basic Information
9.11.2 Neuropore Therapies Neurodegenerative Disease CDMO Product Overview
9.11.3 Neuropore Therapies Neurodegenerative Disease CDMO Product Market Performance
9.11.4 Neuropore Therapies Business Overview
9.11.5 Neuropore Therapies Recent Developments
9.12 Nevrargenics
9.12.1 Nevrargenics Basic Information
9.12.2 Nevrargenics Neurodegenerative Disease CDMO Product Overview
9.12.3 Nevrargenics Neurodegenerative Disease CDMO Product Market Performance
9.12.4 Nevrargenics Business Overview
9.12.5 Nevrargenics Recent Developments
9.13 PPD
9.13.1 PPD Basic Information
9.13.2 PPD Neurodegenerative Disease CDMO Product Overview
9.13.3 PPD Neurodegenerative Disease CDMO Product Market Performance
9.13.4 PPD Business Overview
9.13.5 PPD Recent Developments
9.14 Samsung Biologics
9.14.1 Samsung Biologics Basic Information
9.14.2 Samsung Biologics Neurodegenerative Disease CDMO Product Overview
9.14.3 Samsung Biologics Neurodegenerative Disease CDMO Product Market Performance
9.14.4 Samsung Biologics Business Overview
9.14.5 Samsung Biologics Recent Developments
9.15 Sanofi(Vigil Neuroscience)
9.15.1 Sanofi(Vigil Neuroscience) Basic Information
9.15.2 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Overview
9.15.3 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Market Performance
9.15.4 Sanofi(Vigil Neuroscience) Business Overview
9.15.5 Sanofi(Vigil Neuroscience) Recent Developments
10 NEURODEGENERATIVE DISEASE CDMO MARKET FORECAST BY REGION
10.1 Global Neurodegenerative Disease CDMO Market Size Forecast
10.2 Global Neurodegenerative Disease CDMO Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Neurodegenerative Disease CDMO Market Size Forecast by Country
10.2.3 Asia Pacific Neurodegenerative Disease CDMO Market Size Forecast by Region
10.2.4 South America Neurodegenerative Disease CDMO Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Sales of Neurodegenerative Disease CDMO by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
11.1 Global Neurodegenerative Disease CDMO Market Forecast by Type (2026-2035)
11.1.1 Global Neurodegenerative Disease CDMO Market Size Forecast by Type (2026-2035)
11.2 Global Neurodegenerative Disease CDMO Market Forecast by Application (2026-2035)
11.2.1 Global Neurodegenerative Disease CDMO Market Size (M USD) Forecast by Application (2026-2035)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Neurodegenerative Disease CDMO Market Size by Type (M USD)
Table 4. Global Neurodegenerative Disease CDMO Market Size by Application
Table 5. Neurodegenerative Disease CDMO Market Size Comparison by Region (M USD)
Table 6. Global Neurodegenerative Disease CDMO Revenue (M USD) by Company (2020-2025)
Table 7. Global Neurodegenerative Disease CDMO Revenue Share by Company (2020-2025)
Table 8. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease CDMO as of 2025)
Table 9. Headquarters, Areas Served, and Product Types of Major Players
Table 10. Product Type of Major Players
Table 11. Global Neurodegenerative Disease CDMO Company Market Concentration Ratio (CR5 and HHI)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. Neurodegenerative Disease CDMO Market Challenges
Table 18. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 19. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 20. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 21. Global Neurodegenerative Disease CDMO Market Size by Type (M USD)
Table 22. Global Neurodegenerative Disease CDMO Market Size (M USD) by Type (2020-2025)
Table 23. Global Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
Table 24. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (2021-2025)
Table 25. Global Neurodegenerative Disease CDMO Market Size by Application
Table 26. Global Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (M USD)
Table 27. Global Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Table 28. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application (2021-2025)
Table 29. Global Neurodegenerative Disease CDMO Market Size by Region (2020-2025) & (M USD)
Table 30. Global Neurodegenerative Disease CDMO Market Size Market Share by Region (2020-2025)
Table 31. North America Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (M USD)
Table 32. Europe Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (M USD)
Table 33. Asia Pacific Neurodegenerative Disease CDMO Market Size by Region (2020-2025) & (M USD)
Table 34. South America Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (M USD)
Table 35. Middle East and Africa Neurodegenerative Disease CDMO Market Size by Region (2020-2025) & (M USD)
Table 36. AC Immune Basic Information
Table 37. AC Immune Neurodegenerative Disease CDMO Product Overview
Table 38. AC Immune Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 39. AC Immune SWOT Analysis
Table 40. AC Immune Business Overview
Table 41. AC Immune Recent Developments
Table 42. Alterity Therapeutics Basic Information
Table 43. Alterity Therapeutics Neurodegenerative Disease CDMO Product Overview
Table 44. Alterity Therapeutics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 45. Alterity Therapeutics SWOT Analysis
Table 46. Alterity Therapeutics Business Overview
Table 47. Alterity Therapeutics Recent Developments
Table 48. Biogen Basic Information
Table 49. Biogen Neurodegenerative Disease CDMO Product Overview
Table 50. Biogen Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 51. Biogen SWOT Analysis
Table 52. Biogen Business Overview
Table 53. Biogen Recent Developments
Table 54. Charles River Laboratories Basic Information
Table 55. Charles River Laboratories Neurodegenerative Disease CDMO Product Overview
Table 56. Charles River Laboratories Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 57. Charles River Laboratories Business Overview
Table 58. Charles River Laboratories Recent Developments
Table 59. Coave Therapeutics Basic Information
Table 60. Coave Therapeutics Neurodegenerative Disease CDMO Product Overview
Table 61. Coave Therapeutics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 62. Coave Therapeutics Business Overview
Table 63. Coave Therapeutics Recent Developments
Table 64. Sysmex Corp Basic Information
Table 65. Sysmex Corp Neurodegenerative Disease CDMO Product Overview
Table 66. Sysmex Corp Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 67. Sysmex Corp Business Overview
Table 68. Sysmex Corp Recent Developments
Table 69. Donanemab Basic Information
Table 70. Donanemab Neurodegenerative Disease CDMO Product Overview
Table 71. Donanemab Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 72. Donanemab Business Overview
Table 73. Donanemab Recent Developments
Table 74. Eisai Basic Information
Table 75. Eisai Neurodegenerative Disease CDMO Product Overview
Table 76. Eisai Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 77. Eisai Business Overview
Table 78. Eisai Recent Developments
Table 79. Fujirebio Holdings Basic Information
Table 80. Fujirebio Holdings Neurodegenerative Disease CDMO Product Overview
Table 81. Fujirebio Holdings Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 82. Fujirebio Holdings Business Overview
Table 83. Fujirebio Holdings Recent Developments
Table 84. GenSight Biologics Basic Information
Table 85. GenSight Biologics Neurodegenerative Disease CDMO Product Overview
Table 86. GenSight Biologics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 87. GenSight Biologics Business Overview
Table 88. GenSight Biologics Recent Developments
Table 89. Neuropore Therapies Basic Information
Table 90. Neuropore Therapies Neurodegenerative Disease CDMO Product Overview
Table 91. Neuropore Therapies Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 92. Neuropore Therapies Business Overview
Table 93. Neuropore Therapies Recent Developments
Table 94. Nevrargenics Basic Information
Table 95. Nevrargenics Neurodegenerative Disease CDMO Product Overview
Table 96. Nevrargenics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 97. Nevrargenics Business Overview
Table 98. Nevrargenics Recent Developments
Table 99. PPD Basic Information
Table 100. PPD Neurodegenerative Disease CDMO Product Overview
Table 101. PPD Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 102. PPD Business Overview
Table 103. PPD Recent Developments
Table 104. Samsung Biologics Basic Information
Table 105. Samsung Biologics Neurodegenerative Disease CDMO Product Overview
Table 106. Samsung Biologics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 107. Samsung Biologics Business Overview
Table 108. Samsung Biologics Recent Developments
Table 109. Sanofi(Vigil Neuroscience) Basic Information
Table 110. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Overview
Table 111. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 112. Sanofi(Vigil Neuroscience) Business Overview
Table 113. Sanofi(Vigil Neuroscience) Recent Developments
Table 114. Global Neurodegenerative Disease CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 115. North America Neurodegenerative Disease CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 116. Europe Neurodegenerative Disease CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 117. Asia Pacific Neurodegenerative Disease CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 118. South America Neurodegenerative Disease CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 119. Middle East and Africa Neurodegenerative Disease CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 120. Global Neurodegenerative Disease CDMO Market Size Forecast by Type (2026-2035) & (M USD)
Table 121. Global Neurodegenerative Disease CDMO Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Neurodegenerative Disease CDMO Market Size by Type (M USD)
Table 4. Global Neurodegenerative Disease CDMO Market Size by Application
Table 5. Neurodegenerative Disease CDMO Market Size Comparison by Region (M USD)
Table 6. Global Neurodegenerative Disease CDMO Revenue (M USD) by Company (2020-2025)
Table 7. Global Neurodegenerative Disease CDMO Revenue Share by Company (2020-2025)
Table 8. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease CDMO as of 2025)
Table 9. Headquarters, Areas Served, and Product Types of Major Players
Table 10. Product Type of Major Players
Table 11. Global Neurodegenerative Disease CDMO Company Market Concentration Ratio (CR5 and HHI)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. Neurodegenerative Disease CDMO Market Challenges
Table 18. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 19. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 20. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 21. Global Neurodegenerative Disease CDMO Market Size by Type (M USD)
Table 22. Global Neurodegenerative Disease CDMO Market Size (M USD) by Type (2020-2025)
Table 23. Global Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
Table 24. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (2021-2025)
Table 25. Global Neurodegenerative Disease CDMO Market Size by Application
Table 26. Global Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (M USD)
Table 27. Global Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Table 28. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application (2021-2025)
Table 29. Global Neurodegenerative Disease CDMO Market Size by Region (2020-2025) & (M USD)
Table 30. Global Neurodegenerative Disease CDMO Market Size Market Share by Region (2020-2025)
Table 31. North America Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (M USD)
Table 32. Europe Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (M USD)
Table 33. Asia Pacific Neurodegenerative Disease CDMO Market Size by Region (2020-2025) & (M USD)
Table 34. South America Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (M USD)
Table 35. Middle East and Africa Neurodegenerative Disease CDMO Market Size by Region (2020-2025) & (M USD)
Table 36. AC Immune Basic Information
Table 37. AC Immune Neurodegenerative Disease CDMO Product Overview
Table 38. AC Immune Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 39. AC Immune SWOT Analysis
Table 40. AC Immune Business Overview
Table 41. AC Immune Recent Developments
Table 42. Alterity Therapeutics Basic Information
Table 43. Alterity Therapeutics Neurodegenerative Disease CDMO Product Overview
Table 44. Alterity Therapeutics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 45. Alterity Therapeutics SWOT Analysis
Table 46. Alterity Therapeutics Business Overview
Table 47. Alterity Therapeutics Recent Developments
Table 48. Biogen Basic Information
Table 49. Biogen Neurodegenerative Disease CDMO Product Overview
Table 50. Biogen Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 51. Biogen SWOT Analysis
Table 52. Biogen Business Overview
Table 53. Biogen Recent Developments
Table 54. Charles River Laboratories Basic Information
Table 55. Charles River Laboratories Neurodegenerative Disease CDMO Product Overview
Table 56. Charles River Laboratories Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 57. Charles River Laboratories Business Overview
Table 58. Charles River Laboratories Recent Developments
Table 59. Coave Therapeutics Basic Information
Table 60. Coave Therapeutics Neurodegenerative Disease CDMO Product Overview
Table 61. Coave Therapeutics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 62. Coave Therapeutics Business Overview
Table 63. Coave Therapeutics Recent Developments
Table 64. Sysmex Corp Basic Information
Table 65. Sysmex Corp Neurodegenerative Disease CDMO Product Overview
Table 66. Sysmex Corp Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 67. Sysmex Corp Business Overview
Table 68. Sysmex Corp Recent Developments
Table 69. Donanemab Basic Information
Table 70. Donanemab Neurodegenerative Disease CDMO Product Overview
Table 71. Donanemab Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 72. Donanemab Business Overview
Table 73. Donanemab Recent Developments
Table 74. Eisai Basic Information
Table 75. Eisai Neurodegenerative Disease CDMO Product Overview
Table 76. Eisai Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 77. Eisai Business Overview
Table 78. Eisai Recent Developments
Table 79. Fujirebio Holdings Basic Information
Table 80. Fujirebio Holdings Neurodegenerative Disease CDMO Product Overview
Table 81. Fujirebio Holdings Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 82. Fujirebio Holdings Business Overview
Table 83. Fujirebio Holdings Recent Developments
Table 84. GenSight Biologics Basic Information
Table 85. GenSight Biologics Neurodegenerative Disease CDMO Product Overview
Table 86. GenSight Biologics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 87. GenSight Biologics Business Overview
Table 88. GenSight Biologics Recent Developments
Table 89. Neuropore Therapies Basic Information
Table 90. Neuropore Therapies Neurodegenerative Disease CDMO Product Overview
Table 91. Neuropore Therapies Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 92. Neuropore Therapies Business Overview
Table 93. Neuropore Therapies Recent Developments
Table 94. Nevrargenics Basic Information
Table 95. Nevrargenics Neurodegenerative Disease CDMO Product Overview
Table 96. Nevrargenics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 97. Nevrargenics Business Overview
Table 98. Nevrargenics Recent Developments
Table 99. PPD Basic Information
Table 100. PPD Neurodegenerative Disease CDMO Product Overview
Table 101. PPD Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 102. PPD Business Overview
Table 103. PPD Recent Developments
Table 104. Samsung Biologics Basic Information
Table 105. Samsung Biologics Neurodegenerative Disease CDMO Product Overview
Table 106. Samsung Biologics Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 107. Samsung Biologics Business Overview
Table 108. Samsung Biologics Recent Developments
Table 109. Sanofi(Vigil Neuroscience) Basic Information
Table 110. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Overview
Table 111. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 112. Sanofi(Vigil Neuroscience) Business Overview
Table 113. Sanofi(Vigil Neuroscience) Recent Developments
Table 114. Global Neurodegenerative Disease CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 115. North America Neurodegenerative Disease CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 116. Europe Neurodegenerative Disease CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 117. Asia Pacific Neurodegenerative Disease CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 118. South America Neurodegenerative Disease CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 119. Middle East and Africa Neurodegenerative Disease CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 120. Global Neurodegenerative Disease CDMO Market Size Forecast by Type (2026-2035) & (M USD)
Table 121. Global Neurodegenerative Disease CDMO Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Industry Chain of Neurodegenerative Disease CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurodegenerative Disease CDMO Market Size (M USD), 2025-2035
Figure 5. Global Neurodegenerative Disease CDMO Market Size (M USD) (2020-2035)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Neurodegenerative Disease CDMO Market Size by Country (M USD)
Figure 10. Company Assessment Quadrant
Figure 11. Global Neurodegenerative Disease CDMO Product Life Cycle
Figure 12. Global Neurodegenerative Disease CDMO Revenue Share by Company in 2025
Figure 13. Neurodegenerative Disease CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 14. The Global 5 and 10 Largest Players: Market Share by Neurodegenerative Disease CDMO Revenue in 2025
Figure 15. Value Chain Map of Neurodegenerative Disease CDMO
Figure 16. Global Neurodegenerative Disease CDMO Market PEST Analysis
Figure 17. Global Neurodegenerative Disease CDMO Market Porter's Five Forces Analysis
Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 19. Global Neurodegenerative Disease CDMO Market Share by Type
Figure 20. Market Share of Neurodegenerative Disease CDMO by Type (2020-2025)
Figure 21. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (2021-2025)
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Neurodegenerative Disease CDMO Market Share by Application
Figure 24. Global Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Figure 25. Global Neurodegenerative Disease CDMO Market Share by Application in 2024
Figure 26. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application (2021-2025)
Figure 27. Global Neurodegenerative Disease CDMO Market Size Market Share by Region (2020-2025)
Figure 28. North America Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 29. North America Neurodegenerative Disease CDMO Market Size Market Share by Country in 2024
Figure 30. U.S. Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 31. Canada Neurodegenerative Disease CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 32. Mexico Neurodegenerative Disease CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 33. Europe Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 34. Europe Neurodegenerative Disease CDMO Market Share by Country in 2024
Figure 35. Germany Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 36. France Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 37. U.K. Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 38. Italy Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 39. Spain Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 40. Asia Pacific Neurodegenerative Disease CDMO Market Size and Growth Rate (M USD)
Figure 41. Asia Pacific Neurodegenerative Disease CDMO Market Size Market Share by Region in 2024
Figure 42. China Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 43. Japan Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. South Korea Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 45. India Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. Southeast Asia Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. South America Neurodegenerative Disease CDMO Market Size and Growth Rate (M USD)
Figure 48. South America Neurodegenerative Disease CDMO Market Size Market Share by Country in 2024
Figure 49. Brazil Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 50. Argentina Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Columbia Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 52. Middle East and Africa Neurodegenerative Disease CDMO Market Size and Growth Rate (M USD)
Figure 53. Middle East and Africa Neurodegenerative Disease CDMO Market Size Market Share by Region in 2024
Figure 54. Saudi Arabia Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 55. UAE Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. Egypt Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. Nigeria Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. South Africa Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. Global Neurodegenerative Disease CDMO Market Size Forecast by Value (2020-2035) & (M USD)
Figure 60. Global Neurodegenerative Disease CDMO Market Share Forecast by Type (2026-2035)
Figure 61. Global Neurodegenerative Disease CDMO Market Share Forecast by Application (2026-2035)
Figure 1. Industry Chain of Neurodegenerative Disease CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurodegenerative Disease CDMO Market Size (M USD), 2025-2035
Figure 5. Global Neurodegenerative Disease CDMO Market Size (M USD) (2020-2035)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Neurodegenerative Disease CDMO Market Size by Country (M USD)
Figure 10. Company Assessment Quadrant
Figure 11. Global Neurodegenerative Disease CDMO Product Life Cycle
Figure 12. Global Neurodegenerative Disease CDMO Revenue Share by Company in 2025
Figure 13. Neurodegenerative Disease CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 14. The Global 5 and 10 Largest Players: Market Share by Neurodegenerative Disease CDMO Revenue in 2025
Figure 15. Value Chain Map of Neurodegenerative Disease CDMO
Figure 16. Global Neurodegenerative Disease CDMO Market PEST Analysis
Figure 17. Global Neurodegenerative Disease CDMO Market Porter's Five Forces Analysis
Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 19. Global Neurodegenerative Disease CDMO Market Share by Type
Figure 20. Market Share of Neurodegenerative Disease CDMO by Type (2020-2025)
Figure 21. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (2021-2025)
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Neurodegenerative Disease CDMO Market Share by Application
Figure 24. Global Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Figure 25. Global Neurodegenerative Disease CDMO Market Share by Application in 2024
Figure 26. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application (2021-2025)
Figure 27. Global Neurodegenerative Disease CDMO Market Size Market Share by Region (2020-2025)
Figure 28. North America Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 29. North America Neurodegenerative Disease CDMO Market Size Market Share by Country in 2024
Figure 30. U.S. Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 31. Canada Neurodegenerative Disease CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 32. Mexico Neurodegenerative Disease CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 33. Europe Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 34. Europe Neurodegenerative Disease CDMO Market Share by Country in 2024
Figure 35. Germany Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 36. France Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 37. U.K. Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 38. Italy Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 39. Spain Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 40. Asia Pacific Neurodegenerative Disease CDMO Market Size and Growth Rate (M USD)
Figure 41. Asia Pacific Neurodegenerative Disease CDMO Market Size Market Share by Region in 2024
Figure 42. China Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 43. Japan Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. South Korea Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 45. India Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. Southeast Asia Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. South America Neurodegenerative Disease CDMO Market Size and Growth Rate (M USD)
Figure 48. South America Neurodegenerative Disease CDMO Market Size Market Share by Country in 2024
Figure 49. Brazil Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 50. Argentina Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Columbia Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 52. Middle East and Africa Neurodegenerative Disease CDMO Market Size and Growth Rate (M USD)
Figure 53. Middle East and Africa Neurodegenerative Disease CDMO Market Size Market Share by Region in 2024
Figure 54. Saudi Arabia Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 55. UAE Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. Egypt Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. Nigeria Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. South Africa Neurodegenerative Disease CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. Global Neurodegenerative Disease CDMO Market Size Forecast by Value (2020-2035) & (M USD)
Figure 60. Global Neurodegenerative Disease CDMO Market Share Forecast by Type (2026-2035)
Figure 61. Global Neurodegenerative Disease CDMO Market Share Forecast by Application (2026-2035)
